Answers are grounded in this paper and cite their sources.
Cohort study evaluates the survival impact of capecitabine in women with triple-negative breast cancer post-chemotherapy, suggesting further investigation is needed.
In this real-world cohort, achieving pCR after carboplatin-containing NACT was the strongest determinant of favorable prognosis. Adjuvant capecitabine was not associated with statistically significant improvement in survival outcomes. The role of capecitabine following prior platinum exposure remains uncertain and warrants further investigation.
No takes yet. Share an insight, caveat, or question.
Tavares et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: